VA Opioid Prescription Policy, Practice and Procedures

Date: Thursday, March 26, 2015 Time: 10:00 AM Location: Russell Senate Office Building SR-418

Open in New Window

Agenda

Panel I

Carolyn Clancy, MD, Interim Under Secretary for Health, Veterans Health Administration,

Department of Veterans Affairs

Accompanied By:

Gavin West, MD, Special Assistant for Clinical Operations

Michael Valentino, Chief Consultant of Pharmacy Benefits Management Services


John D. Daigh, Jr., MD, CPA, Assistant Inspector General for Healthcare Inspections,

Office of Inspector General, Department of Veterans Affairs

                                                                                                                                

 --

Panel II

G. Caleb Alexander, MD, Co-Director, Center for Drug Safety and Effectiveness,

Johns Hopkins Bloomberg School of Public Health

Carol Forster, MD, Physician Director, Pharmacy & Therapeutics/Medication Safety,

Mid-Atlantic Permanente Medical Group, Kaiser Permanente 

John Gadea, Director, Drug Control Division, Connecticut Department of Consumer Protection

--

Member Statements

  1. Chairman Johnny Isakson ( R - GA)
  2. Senator Richard Blumenthal ( D - CT)

Witnesses

  1. Dr. Carolyn Clancy
    Deputy Under Secretary for Health
    Veterans Health Administration, Department of Veterans Affairs
  2. Dr. John D. Daigh
    Assistant Inspector General for Healthcare Inspections
    Office of the Inspector General, Department of Veterans Affairs
  3. Dr. G. Caleb Alexander
    Co-Director
    Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health
  4. Dr. Carol Forster
    Physician Director, Pharmacy & Therapeutics/Medication Safety
    Mid-Atlantic Permanente Medical Group, Kaiser Permanente
  5. Mr. John Gadea
    Director
    Drug Control Division, Connecticut Department of Consumer Protection

Disability Access

Individuals with disabilities who require an auxiliary aid or service should contact the committee clerk at (202) 224-9126 at least three business days in advance of the hearing date.